ALV-100 is a bifunctional fusion protein combining glucose-dependent insulinotropic polypeptide receptor (GIPR) antagonism with glucagon-like peptide-1 receptor agonism
SLE remains a life-threatening autoimmune disease, with patients facing an elevated risk of early mortality and long-term organ damage
Heart failure affects an estimated 64.3 million people worldwide
Within India, Dabur expects its Home & Personal Care business to deliver double-digit growth,
The company previously completed a $150 million venture investment, acquisition, and recapitalization
Under the agreement, Insilico could receive up to $32 million in upfront and near-term R&D payments
Abbott’s latest innovation promises to shift diabetes management from reactive to proactive
The FDA acknowledged that Corcept’s pivotal GRACE trial met its primary endpoint and that data from the GRADIENT trial offered confirmatory evidence
He noted the enduring relevance of Siddha medicine as “a comprehensive, preventive and sustainable healthcare system in the contemporary world
Coverage has been significantly strengthened across key therapeutic categories, including anti-tubercular, anti-diabetic and anti-cancer medicines, as well as iron supplements, thereby ensuring more comprehensive standardisation of medicines used under various National Health Programmes
Subscribe To Our Newsletter & Stay Updated
